Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084402 | 1.00 | BRD4 (0.44) | BRD4CREBBP | |
| SCHEMBL15065782 | 1.00 | BRD4 (0.44) | BRD4CREBBP | |
| SCHEMBL15065780 | 1.00 | BRD4 (0.44) | BRD4CREBBP | |
| SCHEMBL15065180 | 0.87 | BRD4 (0.49) | BRD4CREBBP | |
| SCHEMBL15065178 | 0.87 | BRD4 (0.49) | BRD4CREBBP | |
| SCHEMBL15065182 | 0.87 | BRD4 (0.49) | BRD4CREBBP | |
| SCHEMBL15084434 | 0.87 | BRD4 (0.49) | BRD4CREBBP | |
| SCHEMBL15064594 | 0.83 | BRD4 (0.48) | BRD4CREBBP | |
| SCHEMBL15084401 | 0.83 | BRD4 (0.48) | BRD4CREBBP | |
| SCHEMBL15064593 | 0.83 | BRD4 (0.48) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615916-B1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | BRD4 845/4885CREBBP 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.